Conference - Boston, MA, United States
Industrial interest in applying and translating epigenetic science to cancer therapy is growing at an exponential pace with many large and small companies already heavily invested in the field. Fortunately, epigenetics arrives as a science in a more collaborative era and may even have the potential to impact disease areas beyond cancer in the future. The fundamental underpinning science of the epigenome will likely be solved through partnership between academic and industrial labs.
GTC’s 2nd Cancer Epigenetics Conference, one of two parallel tracks of the Cancer Summit - Novel Approaches to Drug Discovery on November 8-9 in Boston, MA, is the only cancer epigenetics conference that brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics. This meeting will be one of the first occasions where recent high profile disclosures made in the likes Nature and Cell will be discussed
http://www.gtcbio.com/component/conference/
Thu, Nov 08, 2012 - Fri, Nov 09, 2012
The Boston Park Plaza Hotel & Towers
50 Park Plaza at Arlington Street Boston, MA 02116, Boston, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
